Chemiluminescence Immunoassay Analyzers Market to grow at a CAGR of 11.72% during 2024-2028
The Chemiluminescence Immunoassay Analyzers Market is expected to grow at a CAGR of 11.72% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 4551.6 million. The global autoimmune diseases diagnostic market is experiencing significant growth due to the increasing prevalence of these conditions worldwide. Central laboratories, which process a large volume of samples, are responding to this trend by automating their analysis processes. Automation streamlines both pre-analytical and post-analytical stages, reducing the need for manual intervention and minimizing errors. Leading vendors, including Abbott Laboratories, Siemens AG, and Roche Diagnostics, provide automated systems for sample analysis. These systems, available as standalone or integrated analyzers, support various assays, including autoimmune diagnostic assays. By automating their processes, laboratories can enhance efficiency, accuracy, and productivity.
Get more information on Chemiluminescence Immunoassay Analyzers Market by requesting a sample report
Technavio analysts predict that the Hospitals subsegment will lead the End-user segment during 2024 and 2028 In the healthcare industry, chemiluminescence immunoassay analyzers play a pivotal role in diagnostic testing, particularly in hospitals for the detection of autoimmune disorders, diabetes, thyroid, hepatitis, HIV, and therapeutic drug monitoring. The global prevalence of diseases such as cancer and diabetes has driven a significant demand for highly sensitive and reliable assays for early and accurate diagnosis. Factors including the rising incidence of infectious diseases and persistent product advancements aimed at faster disease detection further fuel this demand. In the US, reimbursement programs cover certain diagnostic tests, leading to increased adoption of these analyzers for rapid analysis.
Here are the various ways based on which the market is segmented:
There are several factors that are causing the market to flourish higher sensitivity and accuracy of cla over elisa
Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report
The Chemiluminescence Immunoassay (CLIA) market is witnessing significant growth due to the increasing prevalence of chronic diseases such as Hepatitis, Oncology, Endocrinology, Autoimmune diseases, Obesity, Diabetes, HIV, and Cardiovascular diseases. Hospitals, Intensive Care Units, and Emergency Departments are the major end-users of chemiluminescence analyzers due to the high demand for rapid and accurate diagnostic tests. Chemiluminescence technology is the backbone of CLIA, which offers high sensitivity and specificity in detecting antigen-antibody complexes. The market for chemiluminescence analyzers is expanding in various applications, including infectious diseases, cancer, and chronic diseases. The geriatric population is another growing segment due to the increased prevalence of chronic diseases in this population. Point-of-care testing is gaining popularity in various settings, including oncology, endocrinology, and infectious diseases, due to its convenience and quick turnaround time. Luminometers and consumables are essential components of chemiluminescence analyzers, driving the market growth. The market for chemiluminescence immunoassay is expected to grow at a CAGR of over 7% during the forecast period, driven by the increasing demand for accurate and rapid diagnostic tests in various applications.
Technavio's market analysis encompasses the chemiluminescence immunoassay analyzers market as a segment of the expansive global healthcare equipment industry. This sector encompasses entities involved in the research and development (R&D) of various product categories, such as capital equipment, instruments, implants, accessories, and consumables. These products are utilized in the diagnosis, monitoring, and treatment of diverse disease areas. The size of the global healthcare equipment market is determined by Technavio through the consolidated revenue generated by manufacturers of diagnostic equipment and devices. The healthcare equipment sector is segmented into Devices, which incorporates advanced, differentiated, and clinically validated data-driven devices, including chemiluminescence immunoassay analyzers.
The Chemiluminescence Immunoassay Analyzers Market is experiencing significant growth, fueled by the higher sensitivity and accuracy of cla over elisa. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/